Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States

BACKGROUND: Second-generation androgen receptor inhibitors (ARIs) have been associated with adverse events (AEs) such as fatigue, falls, fractures, and rash in non-metastatic castration-resistant prostate cancer (nmCRPC) patients as identified in clinical trials. The objectives of this study were to...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussain, Arif, Jiang, Shan, Varghese, Della, Appukkuttan, Sreevalsa, Kebede, Nehemiah, Gnanasakthy, Kajan, Macahilig, Cynthia, Waldeck, Reg, Corman, Shelby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939229/
https://www.ncbi.nlm.nih.gov/pubmed/35317768
http://dx.doi.org/10.1186/s12885-022-09364-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939229/
https://www.ncbi.nlm.nih.gov/pubmed/35317768
http://dx.doi.org/10.1186/s12885-022-09364-z

Ejemplares similares